Breast cancer

04 June 2012

Drug keeps breast cancer at bay

An experimental drug treatment may help keep a certain kind of aggressive breast cancer at bay, offering new hope for individual therapies against difficult tumours, said research.

0

An experimental drug treatment may help keep a certain kind of aggressive breast cancer at bay, offering new hope for individual therapies against difficult tumours, said research.

The phase III trial comparing trastuzumab emtansine (T-DM1) to standard therapy for human epidermal growth factor receptor 2 (HER2 positive) breast cancer was presented at the American Society of Clinical Oncology conference in Chicago.

The international study randomised nearly 1 000 patients to receive either T-DM1 or standard therapy every three weeks. The subjects all had metastatic cancer that had spread to other parts of the body.

Little dose limiting toxicity

The trial found that progression-free survival in the T-DM1 group was 9.6 months, compared to 6.4 months in the standard therapy group, which study authors described as "clinically meaningful improvement."

"The drug worked. It was significantly better than a very effective approved therapy for HER2 over expressing metastatic breast cancer," said lead study author Kimberly Blackwell, professor of medicine at Duke University.

"Also, as a clinician who takes care of a lot of breast cancer patients, I'm pleased that this drug has very little dose-limiting toxicity. Patients don't lose their hair from this drug.

A breakthrough

"For patients facing metastatic breast cancer, this is a breakthrough."

The data on overall survival time showed 65% of T-DM1 patients were alive after two years, compared to 47.5% of the standard therapy patients, a threshold that fell short of the trial's predetermined limits for judging statistical significance.

More analysis of survival times is planned for later in the ongoing study.

(Sapa, June 2012) 

Raed more:

Breast cancer

Breast cancer treatment side effects last for years

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules